Design Therapeutics (NASDAQ:DSGN) Given "Sell (D-)" Rating at Weiss Ratings

Key Points

• Design Therapeutics (NASDAQ:DSGN) received a "sell (D-)" rating from Weiss Ratings, indicating a bearish outlook on the stock.
• The company's stock recently traded up 6.9%, reaching a price of $6.94, but has shown significant volatility with a 12-month low of $2.60 and a high of $7.77.
• Design Therapeutics reported a quarterly EPS of ($0.34), missing analysts' expectations, and is forecasted to post a -0.91 EPS for the current fiscal year.

Design Therapeutics (NASDAQ:DSGN - Get Free Report)'s stock had its "sell (d-)" rating reiterated by equities research analysts at Weiss Ratings in a report issued on Wednesday,Weiss Ratings reports.

Design Therapeutics Trading Up 6.9%

NASDAQ DSGN traded up $0.45 during trading on Wednesday, reaching $6.94. The company's stock had a trading volume of 173,533 shares, compared to its average volume of 178,705. The firm has a market capitalization of $395.23 million, a price-to-earnings ratio of -6.20 and a beta of 1.68. Design Therapeutics has a 12 month low of $2.60 and a 12 month high of $7.77. The firm has a 50 day moving average price of $5.63 and a 200 day moving average price of $4.44.

Design Therapeutics (NASDAQ:DSGN - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.02). On average, equities analysts forecast that Design Therapeutics will post -0.91 EPS for the current fiscal year.

Institutional Trading of Design Therapeutics

A number of institutional investors have recently bought and sold shares of DSGN. Palumbo Wealth Management LLC lifted its holdings in shares of Design Therapeutics by 6.5% during the 1st quarter. Palumbo Wealth Management LLC now owns 58,278 shares of the company's stock worth $225,000 after acquiring an additional 3,582 shares during the period. Nuveen LLC bought a new stake in shares of Design Therapeutics during the 1st quarter worth approximately $568,000. American Century Companies Inc. lifted its holdings in shares of Design Therapeutics by 13.5% during the 1st quarter. American Century Companies Inc. now owns 44,415 shares of the company's stock worth $171,000 after acquiring an additional 5,300 shares during the period. Wellington Management Group LLP bought a new stake in shares of Design Therapeutics during the 1st quarter worth approximately $546,000. Finally, Driehaus Capital Management LLC lifted its holdings in shares of Design Therapeutics by 17.7% during the 1st quarter. Driehaus Capital Management LLC now owns 913,399 shares of the company's stock worth $3,526,000 after acquiring an additional 137,317 shares during the period. Institutional investors own 56.64% of the company's stock.

Design Therapeutics Company Profile

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.